1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Influenza A Infections - Pipeline Review, H2 2014, Global Markets Direct

Influenza A Infections - Pipeline Review, H2 2014, Global Markets Direct

  • September 2014
  • -
  • Global Markets Direct
  • -
  • 141 pages

Influenza A Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Influenza A Infections - Pipeline Review, H2 2014’, provides an overview of the Influenza A Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza A Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Influenza A Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Influenza A Infections - Pipeline Review, H2 2014, Global Markets Direct
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Influenza A Infections Overview 8
Therapeutics Development 9
Pipeline Products for Influenza A Infections - Overview 9
Pipeline Products for Influenza A Infections - Comparative Analysis 10
Influenza A Infections - Therapeutics under Development by Companies 11
Influenza A Infections - Therapeutics under Investigation by Universities/Institutes 14
Influenza A Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Influenza A Infections - Products under Development by Companies 18
Influenza A Infections - Products under Investigation by Universities/Institutes 21
Influenza A Infections - Companies Involved in Therapeutics Development 22
Johnson and Johnson 22
Kyowa Hakko Kirin Co., Ltd. 23
Autoimmune Technologies, LLC 24
GlaxoSmithKline plc 25
Genentech, Inc. 26
Inovio Pharmaceuticals, Inc. 27
MedImmune, LLC 28
Crucell N.V. 29
Hemispherx Biopharma, Inc. 30
NanoViricides, Inc. 31
SIGA Technologies, Inc. (Inactive) 32
Vironova AB 33
CureVac GmbH 34
Chimerix, Inc. 35
Theraclone Sciences, Inc. 36
Immune Targeting Systems (ITS) Ltd. 37
Sinovac Biotech Ltd. 38
Microbiotix, Inc. 39
iBio, Inc. 40
Alios BioPharma, Inc. 41
Vivaldi Biosciences Inc. 42
Visterra, Inc. 43
ContraFect Corporation 44
Cure Lab, Inc. 45
Humabs BioMed SA 46
Microgen Scientific Industrial Company for Immunobiological Medicines 47
Influenza A Infections - Therapeutics Assessment 48
Assessment by Monotherapy Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
FP-01 - Drug Profile 57
CR-8020 - Drug Profile 58
TCN-032 - Drug Profile 59
influenza vaccine (H5N2) - Drug Profile 61
RG-7745 - Drug Profile 62
diridavumab - Drug Profile 63
MEDI-550 - Drug Profile 65
influenza A vaccine (H7N7) - Drug Profile 67
VIS-410 - Drug Profile 68
Live Attenuated Vaccine for H5N2 Influenza - Drug Profile 69
GSK-3206641A - Drug Profile 70
GSK-3206640A - Drug Profile 71
Influenza A Vaccine [H7N9] - Drug Profile 72
GSK-3277510A - Drug Profile 73
GSK-3277509A - Drug Profile 74
Influenza Vaccine [H7N9] - Drug Profile 75
interferon alfa-n3 - Drug Profile 76
NVINF-2 - Drug Profile 78
Pandemic Influenza Vaccine (H1N1) - Drug Profile 79
Flufirvitide-3 - Drug Profile 80
NVINF-1 - Drug Profile 81
Nucleozin - Drug Profile 83
Small Molecule for Influenza A - Drug Profile 84
ET-001 - Drug Profile 85
CR-8043 - Drug Profile 86
FI-6 - Drug Profile 87
DNA Vaccine for H7N9 Universal Influenza - Drug Profile 88
Peptides for Influenza Infections - Drug Profile 89
Gamma-Flu - Drug Profile 90
Peptide to Agonize PAR-2 for Influenza A Infections - Drug Profile 91
VH-244 - Drug Profile 92
CF-401 - Drug Profile 94
CF-402 - Drug Profile 95
Panavimab A - Drug Profile 96
CLVax-1.0 - Drug Profile 97
Z-3G1 - Drug Profile 99
Small Molecules for Influenza A Infections - Drug Profile 100
Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza A Virus Infections - Drug Profile 101
Small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile 102
Small Molecules to Block Influenza M2 Proton Channel for Influenza A Infections - Drug Profile 103
AL-18 - Drug Profile 104
influenza vaccine (H7N9) - Drug Profile 105
MBX-2329 - Drug Profile 106
MBX-2546 - Drug Profile 108
Recombinant Peptides for HIV-1 Infection and Influenza A Infections - Drug Profile 109
Small Molecule for Influenza Virus - Drug Profile 110
Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 111
VX-353 - Drug Profile 112
Small Molecules to Block M2 Proton Channel for Influenza A Infections - Drug Profile 113
Influenza A Infections - Recent Pipeline Updates 114
Influenza A Infections - Dormant Projects 125
Influenza A Infections - Discontinued Products 126
Influenza A Infections - Product Development Milestones 127
Featured News and Press Releases 127
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 138
Disclaimer 138

List of Tables

Number of Products under Development for Influenza A Infections, H2 2014 12
Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Development by Companies, H2 2014 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2014 24
Influenza A Infections - Pipeline by Johnson and Johnson, H2 2014 25
Influenza A Infections - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 26
Influenza A Infections - Pipeline by Autoimmune Technologies, LLC, H2 2014 27
Influenza A Infections - Pipeline by GlaxoSmithKline plc, H2 2014 28
Influenza A Infections - Pipeline by Genentech, Inc., H2 2014 29
Influenza A Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 30
Influenza A Infections - Pipeline by MedImmune, LLC, H2 2014 31
Influenza A Infections - Pipeline by Crucell N.V., H2 2014 32
Influenza A Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2014 33
Influenza A Infections - Pipeline by NanoViricides, Inc., H2 2014 34
Influenza A Infections - Pipeline by SIGA Technologies, Inc. (Inactive), H2 2014 35
Influenza A Infections - Pipeline by Vironova AB, H2 2014 36
Influenza A Infections - Pipeline by CureVac GmbH, H2 2014 37
Influenza A Infections - Pipeline by Chimerix, Inc., H2 2014 38
Influenza A Infections - Pipeline by Theraclone Sciences, Inc., H2 2014 39
Influenza A Infections - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014 40
Influenza A Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 41
Influenza A Infections - Pipeline by Microbiotix, Inc., H2 2014 42
Influenza A Infections - Pipeline by iBio, Inc., H2 2014 43
Influenza A Infections - Pipeline by Alios BioPharma, Inc., H2 2014 44
Influenza A Infections - Pipeline by Vivaldi Biosciences Inc., H2 2014 45
Influenza A Infections - Pipeline by Visterra, Inc., H2 2014 46
Influenza A Infections - Pipeline by ContraFect Corporation, H2 2014 47
Influenza A Infections - Pipeline by Cure Lab, Inc., H2 2014 48
Influenza A Infections - Pipeline by Humabs BioMed SA, H2 2014 49
Influenza A Infections - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2014 50
Assessment by Monotherapy Products, H2 2014 51
Number of Products by Stage and Target, H2 2014 53
Number of Products by Stage and Mechanism of Action, H2 2014 55
Number of Products by Stage and Route of Administration, H2 2014 57
Number of Products by Stage and Molecule Type, H2 2014 59
Influenza A Infections Therapeutics - Recent Pipeline Updates, H2 2014 117
Influenza A Infections - Dormant Projects, H2 2014 128
Influenza A Infections - Discontinued Products, H2 2014 129

List of Figures

Number of Products under Development for Influenza A Infections, H2 2014 12
Number of Products under Development for Influenza A Infections - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 14
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Products, H2 2014 20
Assessment by Monotherapy Products, H2 2014 51
Number of Products by Top 10 Target, H2 2014 52
Number of Products by Stage and Top 10 Target, H2 2014 53
Number of Products by Top 10 Mechanism of Action, H2 2014 54
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 55
Number of Products by Top 10 Route of Administration, H2 2014 56
Number of Products by Stage and Top 10 Route of Administration, H2 2014 57
Number of Products by Top 10 Molecule Type, H2 2014 58
Number of Products by Stage and Top 10 Molecule Type, H2 2014 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Influenza
Therapy
Vaccine

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.